NASDAQ:ALZN

Alzamend Neuro - ALZN News Today

$0.37

-0.03 (-6.40%)

(As of 03/20/2023 03:09 PM ET)

Add

Compare

Today's Range: $0.31
▼
$0.40
50-Day Range: $0.40
▼
$0.71
52-Week Range: $0.31
▼
$1.50

Volume: 457,900 shs
Average Volume: 221,441 shs
Market Capitalization: $36.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

Get Alzamend Neuro News Delivered to You Automatically

ALZN Media Mentions By Week

ALZN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALZN
News Sentiment
▼
0.08

0.35
▲
Average
Medical
News Sentiment

ALZN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALZN Articles
This Week
▼
4

0
▲
ALZN Articles
Average Week

Source

Source	Headline
	We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully finance.yahoo.com - March 17 at 8:29 AM
	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update finance.yahoo.com - March 16 at 9:44 AM
	Alzamend Neuro Inc. barrons.com - February 21 at 12:23 AM
	Alzamend Neuro to Present at Sequire Biotechnology Conference finance.yahoo.com - January 26 at 9:47 AM
	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial finance.yahoo.com - January 4 at 9:31 AM
	EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia finance.yahoo.com - December 28 at 1:24 PM
	Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type finance.yahoo.com - December 28 at 8:23 AM
	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. finance.yahoo.com - November 22 at 7:05 PM
	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline finance.yahoo.com - November 15 at 9:38 AM
	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type finance.yahoo.com - October 31 at 12:38 PM
	Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by private companies finance.yahoo.com - October 11 at 10:49 AM
	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer's Subjects benzinga.com - October 7 at 8:58 PM
	Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial finance.yahoo.com - October 5 at 7:15 PM
	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects finance.yahoo.com - October 5 at 9:14 AM
	Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study finance.yahoo.com - September 29 at 4:21 PM
	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type finance.yahoo.com - September 29 at 11:21 AM
	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement finance.yahoo.com - September 22 at 11:14 AM
	Thinking about buying stock in Purple Innovation, Knowbe4, Allakos, Larimar Therapeutics, or Alzamend Neuro? benzinga.com - September 19 at 9:38 AM
	Daily Sports Smile: MLB pitcher and wife create limited edition wine to benefit neurological nonprofit usatoday.com - September 9 at 6:54 PM
	We Think Alzamend Neuro (NASDAQ:ALZN) Can Afford To Drive Business Growth finance.yahoo.com - August 25 at 9:04 AM
	Alzamend Neuro aiming to rapidly develop and market safe and effective treatments for Alzheimer's proactiveinvestors.com - August 12 at 12:31 PM
	A few Alzamend Neuro, Inc. (NASDAQ:ALZN) insiders sold shares in the last 12 months: Not a good sign for shareholders nasdaq.com - July 23 at 9:32 AM
	Alzamend Neuro receives positive pre-IND response from FDA for AL001 seekingalpha.com - July 19 at 8:52 PM
	Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate finance.yahoo.com - July 18 at 2:50 PM
	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder finance.yahoo.com - July 18 at 9:49 AM
	Alzamend Neuro to Present at the 12th Annual LD Micro Invitational finance.yahoo.com - June 3 at 9:56 AM
	Alzamend submits application to begin trial for AL001 to treat bipolar disorder, major depressive disorder seekingalpha.com - May 17 at 4:15 PM
	Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder finance.yahoo.com - May 17 at 9:08 AM
	Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s finance.yahoo.com - May 5 at 10:00 AM
	What Kind Of Investors Own Most Of Alzamend Neuro, Inc. (NASDAQ:ALZN)? finance.yahoo.com - May 4 at 8:16 AM
	Friday 4/29 Insider Buying Report: ALZN, BX nasdaq.com - April 29 at 12:35 PM
	BitNile Reports Added $10M Investment In Alzamend Neuro benzinga.com - April 28 at 8:04 AM
	Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s finance.yahoo.com - April 28 at 8:04 AM
	BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s finance.yahoo.com - April 28 at 8:04 AM
	Wednesday 4/13 Insider Buying Report: CCCC, ALZN nasdaq.com - April 13 at 2:57 PM
	Alzamend ties up with Altasciences and iResearch Atlanta for Alzheimer’s drug trial seekingalpha.com - April 11 at 7:38 PM
	Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s finance.yahoo.com - April 11 at 8:33 AM
	Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board finance.yahoo.com - April 4 at 9:22 AM
	Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s finance.yahoo.com - March 28 at 8:50 AM
	Alzamend Neuro 19% higher following large shareholder buy seekingalpha.com - March 22 at 6:11 PM
	We're Hopeful That Alzamend Neuro (NASDAQ:ALZN) Will Use Its Cash Wisely finance.yahoo.com - March 18 at 9:34 AM
	ALZN: Coordinated Offensive on Alzheimer’s Disease finance.yahoo.com - January 13 at 12:09 PM
	Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s finance.yahoo.com - December 17 at 1:31 PM
	Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate finance.yahoo.com - December 17 at 1:31 PM
	Pre-market Movers: IDRA, GRTX, SEAC, ALZN, SIDU… markets.businessinsider.com - December 15 at 8:45 PM
	Why Alzamend Neuro Stock Soared Today finance.yahoo.com - December 14 at 11:14 PM
	Pre-market Movers: XCUR, MIND, NES, APTO, ALZN… markets.businessinsider.com - December 14 at 8:13 AM
	Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s finance.yahoo.com - November 30 at 1:46 PM
	Alzamend Neuro 10%+ Owner Milton C Ault III Reported Purchase of 19,681 Shares @ Avg Price of $1.92/Share in Form 4 Filing on Tuesday benzinga.com - November 24 at 7:27 AM
	Alzamend Neuro, Inc. (ALZN) realmoney.thestreet.com - November 6 at 10:37 PM

Get Alzamend Neuro News Delivered to You Automatically

This page (NASDAQ:ALZN) was last updated on 3/20/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Alzamend Neuro - ALZN News Today

ALZN Media Mentions By Week

ALZN Media Sentiment

ALZN News Coverage

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info